Skip to Main Content

Paper Details

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Blood
42
2022
Author NameAffiliation
Daniel J DeAngeloDana-Farber Cancer Institute
  • 1 - 1

Datasets

Release 1.2